Cataract Clinical Trial
Official title:
Depth of Focus Comparison Between Acrysof IQ and Acrysof Natural IOLs
The purpose of this study is to evaluate and compare the depth of focus and visual outcomes after implantation of the Acrysof IQ SN60WF aspheric intraocular lens (IOL) and the Acrysof Natural SN60AT spherical IOL.
Cataract is prevalent throughout the world and IOLs are routinely implanted after the
extraction of the cataractous lens. It is the most frequently performed surgery in the United
States with an estimated 2-3 million procedures performed annually. With the aging population
on the rise, as well as the increasing popularity of refractive intraocular lenses, the
number of intraocular surgeries continues to rise.
Over the years, evolution of IOLs has broadened surgeon's armamentarium following cataract
extraction. Traditionally spherical IOLs have been routinely implanted following cataract
extraction for the correction of aphakia. Even though these IOLs improved the patient vision
to 20/20 in most of the times, they did nott address the spherical aberration of the optical
system.
Normally the cornea has a positive spherical aberration. Spherical aberration means that the
light rays falling on the eye's periphery are either more (positive spherical aberration) or
less (negative spherical aberration) refracted than the axial rays. Such aberration usually
affects the functional vision of the patient such as contrast sensitivity, depth of focus
(ability to see far, near and intermediate) and the perception of glare and haloes. Corneal
spherical aberration is adequately neutralized by the negative spherical aberration of the
crystalline lens until the age of 40. (1) When the cataractous lens is removed, the corneal
spherical aberration is no longer neutralized and the optical system will have now a net
positive spherical aberration.
Conventional IOLs implanted after phacoemulsification result in a spherical aberration of
approximately 0.08 µm adding to the already positive corneal aberration of the eye. (2, 3) In
order for the patient to reach the optimal functional vision, efforts have led to the
development of the aspheric IOLs. Aspheric IOLs compensate for the positive spherical
aberration of the cornea. They have been shown to improve the functional vision and optical
quality in pseudophakic patients. (4, 5)
Acrysof IQ, an aspheric IOL was introduced after gaining FDA approval in May 2006. Its shares
the basic design features of the Acrysof Natural IOL with the modifications of its optic
design to acquire a posterior prolate surface reducing its central thickness. Unlike the
cornea, it introduces negative spherical aberration (0.2 µm) that lowers the spherical
aberration of the eye.(6) It has been reported to provide better contrast sensitivity,
quality of vision and fewer aberration with the aspheric IOL compared to the conventional
(spherical) IOL.(6,7,8) However, some studies have found that conventional (spherical) IOLs
have better depth of focus than aspheric IOLs allowing the patient to achieve better
intermediate and near vision.(5) Conversely, Mester et al found no difference in depth of
focus between both IOLs.(7)
The purpose of this study is to evaluate and compare depth of focus and visual outcomes in
eyes receiving the aspheric Acrysof IQ and those receiving the spherical Acrysof Natural IOL
after routine cataract extraction.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |